New recommendations on the use of products containing domperidone

HSA, in consultation with its Medicines Advisory Committee, has issued a Dear Healthcare Professional Letter to inform healthcare professionals about the new recommendations on the use of domperidone due to the potential risk of serious cardiovascular (CV) events associated with its use. HSA’s benefit-risk assessment took into consideration the long-established use of domperidone for the treatment of nausea, vomiting and dyspepsia, isolated CV events reported locally, the lack of suitable therapeutic alternatives, the input of local clinical experts and international regulatory actions. It was concluded that the benefit-risk profile of domperidone for treatment of dyspepsia, nausea and vomiting remains favourable if additional measures are taken to mitigate the risk of cardiotoxicity. Please refer to the letter for details.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.